Medicare launches temporary GLP-1 weight-loss drug access with $50 copay
Medicare's GLP-1 Bridge Program runs July 1, 2026 through December 31, 2027, giving Part D beneficiaries access to GLP-1 weight‑loss medications (Wegovy, Ozempic, Zepbound, Foundayo) prescribed for weight loss with a flat $50 copay. Eligibility uses BMI thresholds (no underlying condition: BMI 35+; with condition: BMI 27+). The program is managed centrally outside standard Part D; providers submit prior authorization, and coverage is nationwide. The drugs covered include Wegovy and Foundayo, plus Zepbound KwikPen. The $50 copay doesn't count toward deductibles or the out‑of‑pocket limit. GLP‑1 drugs can yield 14–20% weight loss per year, but stopping typically leads to regain and side effects like nausea; the drugs are often intended to be used long‑term.
